



[Home](#) / [Investors](#) / [News Releases](#)

Jody LoMenzo Named Director, Investor Relations and Corporate Communications

RICHMOND, Va., Oct 31, 2006 (BUSINESS WIRE) -- Insmed, Inc. (NASDAQ:INSM) announced today that Jody M. LoMenzo has joined the company to serve as Director, Investor Relations and Corporate Communications.

Over the course of her professional career, Ms. LoMenzo has served in senior communications roles for Fortune companies, start-ups, and non-profits, including: the medical-surgical division of McKesson Inc. as marketing communications director; United Dominion Realty Trust, as director of investor relations and corporate communications; Infineon Technologies (White Oak Semiconductor) as communications director; and as administrative director for marketing and public relations at Bon Secours Richmond Health System.

Ms. LoMenzo also has experience on the agency side, working as director of strategic communications for the public relations division of The Martin Agency. She owned and operated her own communications strategy firm, working with healthcare clients in biotechnology and pharmaceuticals to introduce and promote new drugs. Of note, her work with Genentech for the launch of tPA, SmithKline for its Hivagen test, Amgen for Neupogen, Fujisawa for Ganite, BristolMeyer-Squibb for Cardio Tec, Sandoz for Eldyprl, and Lederle for Suprax.

Ms. LoMenzo began her professional career in television, working in New York City, as a news editor for ABC-TV's Good Morning America and as associate producer at CBS News. She received an Emmy nomination while at WABC-TV for her work as special projects producer. A graduate of New York University, she resides in Richmond.

About Insmed

Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.

Forward Looking Statements

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the pending litigation and or future ability to conduct our business as now conducted and as it is currently proposed to be conducted. Such forward-looking statements are subject to numerous risks and uncertainties, including but not limited to the uncertainty of the outcome of any litigation with Tercica, the risk that product candidates may fail in the clinic or may not be successfully marketed or manufactured, the company may lack financial resources to complete development of product candidates or the FDA or other regulatory agencies may interpret the results of our studies differently than we have. We can give no assurances that we would be successful in any litigation or that such litigation would not have a material adverse effect on our business, financial condition and results of operation. Furthermore, we may not be able to afford the expense of defending against such a claim. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.
